These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27943462)

  • 1. Mechanistic target of rapamycin complex 1 is involved in psoriasis and regulated by anti-TNF-α treatment.
    Balato A; Lembo S; Ayala F; Balato N; Caiazzo G; Raimondo A; Di Caprio R; Monfrecola G
    Exp Dermatol; 2017 Apr; 26(4):325-327. PubMed ID: 27943462
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment with TNF-α inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation.
    Lin SH; Chuang HY; Ho JC; Lee CH; Hsiao CC
    J Dermatol Sci; 2018 Sep; 91(3):276-284. PubMed ID: 29914850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-α.
    Langkilde A; Olsen LC; Sætrom P; Drabløs F; Besenbacher S; Raaby L; Johansen C; Iversen L
    PLoS One; 2016; 11(12):e0167437. PubMed ID: 28005985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-α treatment in psoriasis.
    Luan L; Han S; Wang H; Liu X
    Int Immunopharmacol; 2015 Dec; 29(2):278-284. PubMed ID: 26585971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Levels of Platelet-Lymphocyte Complexes in Patients with Psoriasis Are Associated with a Better Response to Anti-TNF-α Therapy.
    Sanz-Martínez MT; Moga E; Sánchez Martínez MA; Zamora Atenza C; Vidal S; Juárez C; Puig L
    J Invest Dermatol; 2020 Jun; 140(6):1176-1183. PubMed ID: 31778714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease.
    Navarrete-Dechent C; Majerson D; Torres M; Armijo D; Patel M; Menter A; de la Cruz C
    An Bras Dermatol; 2015; 90(3 Suppl 1):171-4. PubMed ID: 26312707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNF-α therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study.
    Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Corrales A; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Llorca J; Gonzalez-Gay MA
    J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):92-5. PubMed ID: 25650695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Adalimumab on Gene Expression Profiles of Psoriatic Skin and Blood.
    Chow M; Lai K; Ahn R; Gupta R; Arron S; Liao W
    J Drugs Dermatol; 2016 Aug; 15(8):988-94. PubMed ID: 27538000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of a granulomatous mastitis and aseptic osteitis after anti-TNF therapy in a patient with pustular psoriasis.
    Garraud T; Barbarot S; Berthelot JM; Le Goff B
    Joint Bone Spine; 2016 Jan; 83(1):107-8. PubMed ID: 26054447
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study.
    Pina T; Corrales A; Lopez-Mejias R; Armesto S; Gonzalez-Lopez MA; Gómez-Acebo I; Ubilla B; Remuzgo-Martínez S; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
    J Dermatol; 2016 Nov; 43(11):1267-1272. PubMed ID: 27062420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-TNF biosimilars in psoriasis treatment].
    Viguier M;
    Ann Dermatol Venereol; 2019; 146(6-7):492-496. PubMed ID: 31239173
    [No Abstract]   [Full Text] [Related]  

  • 14. Reflectance confocal microscopy for plaque psoriasis therapeutic follow-up during an anti-TNF-α monoclonal antibody: an observational multicenter study.
    Ardigò M; Agozzino M; Longo C; Lallas A; Di Lernia V; Fabiano A; Conti A; Sperduti I; Argenziano G; Berardesca E; Pellacani G
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2363-8. PubMed ID: 26299420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis.
    Yanaba K; Umezawa Y; Honda H; Sato R; Chiba M; Kikuchi S; Asahina A; Nakagawa H
    J Dermatol; 2016 Apr; 43(4):443-4. PubMed ID: 26662275
    [No Abstract]   [Full Text] [Related]  

  • 16. Langerhans cell markers CD1a and CD207 are the most rapidly responding genes in lesional psoriatic skin following adalimumab treatment.
    Raaby L; Rosada C; Langkilde A; Lauridsen KL; Vinter H; Ommen P; Kjellerup RB; Johansen C; Iversen L
    Exp Dermatol; 2017 Sep; 26(9):804-810. PubMed ID: 28109175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness of adalimumab treatment for non-infectious uveitis.
    Hasegawa E; Takeda A; Yawata N; Sonoda KH
    Immunol Med; 2019 Jun; 42(2):79-83. PubMed ID: 31315546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-146a-5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor-alpha inhibitor adalimumab.
    Mensà E; Recchioni R; Marcheselli F; Giuliodori K; Consales V; Molinelli E; Prattichizzo F; Rippo MR; Campanati A; Procopio AD; Olivieri F; Offidani AM
    Br J Dermatol; 2018 Sep; 179(3):787-789. PubMed ID: 29624637
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy.
    Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1995-2001. PubMed ID: 25823684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.